PACTG 1038: HIGH DOSE LOPINAVIR/RITONAVIR W/ OR W/OUT SAQUINAVIR IN HIV

PACTG 1038：高剂量洛匹那韦/利托那韦（含或不含沙奎那韦）治疗 HIV

• 批准号: 7607270
• 负责人: Kenneth McIntosh
• 金额: $ 1.3万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607270
• 关键词: Adolescent; Anti-Retroviral Agents; Child; Computer Retrieval of Information on Scientific Projects Database; Dose; Drug Kinetics; Funding; Grant; HIV; Institution; Lopinavir/Ritonavir; Protease Inhibitor; Research; Research Personnel; Resources; Safety; Saquinavir; Source; Treatment Protocols; United States National Institutes of Health; experience; non-nucleoside reverse transcriptase inhibitors

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary: 1. To determine the safety and tolerability of high dose LPV/r in Group 1 (400/100 mg/m2 PO Q12H) and Group 2 (480/120 mg/m2 PO Q12H) with concurrent NNRTI treatment. 2. To evaluate the safety and tolerability of saquinavir (750 mg/m2 or 1200 mg/m2 PO Q12H) in combination with LPV/r in children and adolescents (Step 2 and Step 3). 3. To estimate pharmacokinetic parameters for LPV/r and saquinavir in protease inhibitor experienced HIV-infected children and adolescents receiving combination antiretroviral regimens.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 基本的： 1. 确定第 1 组（400/100 mg/m2 PO Q12H）和第 2 组（480/120 mg/m2 PO Q12H）中高剂量 LPV/r 与同时 NNRTI 治疗的安全性和耐受性。 2. 评估沙奎那韦（750 mg/m2 或 1200 mg/m2 PO Q12H）联合 LPV/r 在儿童和青少年中的安全性和耐受性（步骤 2 和步骤 3）。 3. 评估感染 HIV 的儿童和青少年接受联合抗逆转录病毒治疗方案时 LPV/r 和沙奎那韦的药代动力学参数。